Key PointsThe Schwab U.S. Dividend Equity ETF offers a 3.3% yield and a defensive tilt.

If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys

Key PointsAbbVie is the exact opposite of a high-yield trap.

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

Key PointsAbbVie is a resilient Dividend King with a wide moat.

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

(RTTNews) - The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment

FDA Drug Approvals In September 2026 

(RTTNews) - AbbVie Inc. (ABBV) on Tuesday announced that it presented new Phase 3 AFFIRM trial data showing endoscopic remission and ulcer-free endoscopy outcomes with subcutaneous Skyrizi in adults with active Crohn's disease.

AbbVie Reports 35.8% Endoscopic Remission With Subcutaneous Skyrizi In Crohn's Trial 

(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.

AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases 

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. News